Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I

I. Nestrasil, E. Shapiro, A. Svatkova, P. Dickson, A. Chen, A. Wakumoto, A. Ahmed, E. Stehel, S. McNeil, C. Gravance, E. Maher,

. 2017 ; 173 (3) : 780-783.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016764

Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disease that seriously affects the brain. Severity of neurocognitive symptoms in attenuated MPS subtype (MPS IA) broadly varies partially, due to restricted permeability of blood-brain barrier (BBB) which limits treatment effects of intravenously applied α-L-iduronidase (rhIDU) enzyme. Intrathecal (IT) rhIDU application as a possible solution to circumvent BBB improved brain outcomes in canine models; therefore, our study quantifies effects of IT rhIDU on brain structure and function in an MPS IA patient with previous progressive cognitive decline. Neuropsychological testing and MRIs were performed twice prior (baseline, at 1 year) and twice after initiating IT rhIDU (at 2nd and 3rd years). The difference between pre- and post-treatment means was evaluated as a percentage of the change. Neurocognitive performance improved particularly in memory tests and resulted in improved school performance after IT rhIDU treatment. White matter (WM) integrity improved together with an increase of WM and corpus callosum volumes. Hippocampal and gray matter volume decreased which may either parallel reduction of glycosaminoglycan storage or reflect typical longitudinal brain changes in early adulthood. In conclusion, our outcomes suggest neurological benefits of IT rhIDU compared to the intravenous administration on brain structure and function in a single MPS IA patient.© 2017 Wiley Periodicals, Inc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016764
003      
CZ-PrNML
005      
20180518111126.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajmg.a.38073 $2 doi
035    __
$a (PubMed)28211988
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nestrasil, Igor $u University of Minnesota, Minneapolis, Minnesota.
245    10
$a Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I / $c I. Nestrasil, E. Shapiro, A. Svatkova, P. Dickson, A. Chen, A. Wakumoto, A. Ahmed, E. Stehel, S. McNeil, C. Gravance, E. Maher,
520    9_
$a Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disease that seriously affects the brain. Severity of neurocognitive symptoms in attenuated MPS subtype (MPS IA) broadly varies partially, due to restricted permeability of blood-brain barrier (BBB) which limits treatment effects of intravenously applied α-L-iduronidase (rhIDU) enzyme. Intrathecal (IT) rhIDU application as a possible solution to circumvent BBB improved brain outcomes in canine models; therefore, our study quantifies effects of IT rhIDU on brain structure and function in an MPS IA patient with previous progressive cognitive decline. Neuropsychological testing and MRIs were performed twice prior (baseline, at 1 year) and twice after initiating IT rhIDU (at 2nd and 3rd years). The difference between pre- and post-treatment means was evaluated as a percentage of the change. Neurocognitive performance improved particularly in memory tests and resulted in improved school performance after IT rhIDU treatment. White matter (WM) integrity improved together with an increase of WM and corpus callosum volumes. Hippocampal and gray matter volume decreased which may either parallel reduction of glycosaminoglycan storage or reflect typical longitudinal brain changes in early adulthood. In conclusion, our outcomes suggest neurological benefits of IT rhIDU compared to the intravenous administration on brain structure and function in a single MPS IA patient.© 2017 Wiley Periodicals, Inc.
650    _2
$a kognitivní dysfunkce $x farmakoterapie $7 D060825
650    12
$a enzymová substituční terapie $x škodlivé účinky $x metody $7 D056947
650    _2
$a lidé $7 D006801
650    _2
$a iduronidasa $x aplikace a dávkování $x škodlivé účinky $7 D007068
650    _2
$a spinální injekce $7 D007278
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mukopolysacharidóza I $x diagnóza $x farmakoterapie $x psychologie $7 D008059
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a fenotyp $7 D010641
650    _2
$a výsledek terapie $7 D016896
650    _2
$a bílá hmota $x účinky léků $x patologie $7 D066127
650    _2
$a mladý dospělý $7 D055815
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Shapiro, Elsa $u University of Minnesota, Minneapolis, Minnesota.
700    1_
$a Svatkova, Alena $u University of Minnesota, Minneapolis, Minnesota. Multimodal and Functional Neuroimaging Research Group, CEITEC-Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Dickson, Patricia $u Los Angeles Biomedical Institute at Harbor-UCLA, Torrance, California.
700    1_
$a Chen, Agnes $u Los Angeles Biomedical Institute at Harbor-UCLA, Torrance, California.
700    1_
$a Wakumoto, Amy $u University of Minnesota, Minneapolis, Minnesota.
700    1_
$a Ahmed, Alia $u University of Minnesota, Minneapolis, Minnesota.
700    1_
$a Stehel, Edward $u University of Texas Southwestern Medical Center, Dallas, Texas.
700    1_
$a McNeil, Sarah $u University of Texas Southwestern Medical Center, Dallas, Texas.
700    1_
$a Gravance, Curtis $u Ryan Foundation, Carrollton, Texas.
700    1_
$a Maher, Elizabeth $u University of Texas Southwestern Medical Center, Dallas, Texas.
773    0_
$w MED00012678 $t American journal of medical genetics. Part A $x 1552-4833 $g Roč. 173, č. 3 (2017), s. 780-783
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28211988 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180518111304 $b ABA008
999    __
$a ok $b bmc $g 1300388 $s 1013604
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 173 $c 3 $d 780-783 $i 1552-4833 $m American journal of medical genetics. Part A $n Am J Med Genet $x MED00012678
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace